The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 25, 2025 | Orbimed Advisors LLC | Director | Grant(A) | 84K | $2.49 | $208K |
| Jun 7, 2024 | Hughes Owen | Director | Grant(A) | 18K | — | $0 |
| Jun 7, 2024 | Bonita David P | Director | Grant(A) | 18K | — | $0 |
| Jun 7, 2024 | Formela Jean Francois | Director | Grant(A) | 18K | — | $0 |
| Jun 7, 2024 | Stampacchia Otello | Director | Grant(A) | 18K | — | $0 |
| Jun 7, 2024 | Koehler Maria | Director | Grant(A) | 18K | — | $0 |
| Jun 7, 2024 | Dukes Iain D. | Director | Grant(A) | 18K | — | $0 |
| Jun 7, 2024 | Wooster Richard | Director | Grant(A) | 18K | — | $0 |
| Mar 1, 2024 | Germa Caroline | Chief Medical Officer | Grant(A) | 579K | — | $0 |
| Feb 1, 2024 | Manfredi Mark | President & CEO, Director | Grant(A) | 320K | — | $0 |
| Feb 1, 2024 | Marango Jotin | CFO & Head of Corp. Dev. | Grant(A) | 181K | — | $0 |
| Feb 1, 2024 | Ecsedy Jeffrey | Chief Development Officer | Grant(A) | 100K | — | $0 |
| Aug 4, 2023 | OrbiMed Capital GP VI LLC | Director | Grant(A) | 153K | — | — |
| Aug 4, 2023 | OrbiMed Capital GP VI LLC | Director | Grant(A) | 353K | — | — |
| Aug 4, 2023 | Orbimed Advisors LLC | Director | Grant(A) | 153K | — | — |
| Aug 4, 2023 | Orbimed Advisors LLC | Director | Grant(A) | 353K | — | — |
| Aug 4, 2023 | Bonita David P | Director | Grant(A) | 153K | — | — |
| Aug 4, 2023 | Bonita David P | Director | Grant(A) | 353K | — | — |
| Jun 9, 2023 | Wooster Richard | Director | Grant(A) | 18K | — | $0 |
| Jun 9, 2023 | Formela Jean Francois | Director | Grant(A) | 18K | — | $0 |
| Jun 9, 2023 | Stampacchia Otello | Director | Grant(A) | 18K | — | $0 |
| Jun 9, 2023 | Bonita David P | Director | Grant(A) | 18K | — | $0 |
| Jun 9, 2023 | Hughes Owen | Director | Grant(A) | 18K | — | $0 |
| Jun 9, 2023 | Dukes Iain D. | Director | Grant(A) | 18K | — | $0 |
| Jun 9, 2023 | Koehler Maria | Director | Grant(A) | 18K | — | $0 |
| Jan 3, 2023 | Manfredi Mark | President & CEO, Director | Grant(A) | 220K | — | $0 |
| Jan 3, 2023 | Marango Jotin | CFO & Head of Corp. Dev. | Grant(A) | 105K | — | $0 |
| Jan 3, 2023 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Grant(A) | 105K | — | $0 |
| Jan 3, 2023 | Ecsedy Jeffrey | Chief Development Officer | Grant(A) | 105K | — | $0 |
| Jan 3, 2023 | Santillana Sergio L. | Chief Medical Officer | Grant(A) | 105K | — | $0 |
| Dec 15, 2022 | Hughes Owen | Director | Grant(A) | 35K | — | $0 |
| Jun 24, 2022 | Bonita David P | Director | Sell(P) | 66K | $4.37 | $288K |
| Jun 24, 2022 | Bonita David P | Director | Sell(P) | 96K | $5.37 | $516K |
| Jun 24, 2022 | OrbiMed Capital GP VI LLC | Director | Sell(P) | 66K | $4.37 | $288K |
| Jun 24, 2022 | OrbiMed Capital GP VI LLC | Director | Sell(P) | 96K | $5.37 | $516K |
| Jun 23, 2022 | Bonita David P | Director | Sell(P) | 23K | $3.71 | $87K |
| Jun 23, 2022 | OrbiMed Capital GP VI LLC | Director | Sell(P) | 23K | $3.71 | $87K |
| Jun 22, 2022 | Bonita David P | Director | Sell(P) | 67K | $3.55 | $237K |
| Jun 22, 2022 | OrbiMed Capital GP VI LLC | Director | Sell(P) | 67K | $3.55 | $237K |
| Jun 9, 2022 | Koehler Maria | Director | Grant(A) | 13K | — | $0 |
| Jun 9, 2022 | Wooster Richard | Director | Grant(A) | 13K | — | $0 |
| Jun 9, 2022 | Bonita David P | Director | Grant(A) | 13K | — | $0 |
| Jun 9, 2022 | Formela Jean Francois | Director | Grant(A) | 13K | — | $0 |
| Jun 9, 2022 | Renaud Ronald C JR | Director | Grant(A) | 13K | — | $0 |
| Jun 9, 2022 | Dukes Iain D. | Director | Grant(A) | 13K | — | $0 |
| Jun 9, 2022 | Stampacchia Otello | Director | Grant(A) | 13K | — | $0 |
| Apr 25, 2022 | Marango Jotin | CFO & Head of Corp. Dev. | Grant(A) | 397K | — | $0 |
| Feb 3, 2022 | Manfredi Mark | President & CEO, Director | Grant(A) | 239K | — | $0 |
| Feb 2, 2022 | Tessier Maude | Chief Business Officer | Grant(A) | 40K | — | $0 |
| Feb 2, 2022 | Ecsedy Jeffrey | Chief Development Officer | Grant(A) | 59K | — | $0 |
| Feb 2, 2022 | Santillana Sergio L. | Chief Medical Officer | Grant(A) | 70K | — | $0 |
| Feb 2, 2022 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Grant(A) | 40K | — | $0 |
| Jan 21, 2022 | Wooster Richard | Director | Grant(A) | 29K | — | $0 |
| Jan 18, 2022 | Tessier Maude | Chief Business Officer | Option exercise(M) | 8K | $4.51 | $37K |
| Jan 18, 2022 | Tessier Maude | Chief Business Officer | Option exercise(M) | 25K | $4.15 | $102K |
| Jan 18, 2022 | Tessier Maude | Chief Business Officer | Option exercise(M) | 39K | $2.94 | $114K |
| Jan 18, 2022 | Tessier Maude | Chief Business Officer | Option exercise(M) | 25K | — | $0 |
| Jan 18, 2022 | Tessier Maude | Chief Business Officer | Option exercise(M) | 8K | — | $0 |
| Jan 18, 2022 | Tessier Maude | Chief Business Officer | Option exercise(M) | 39K | — | $0 |
| Jan 11, 2022 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Sell(S) | 964 | $12.00 | $12K |
| Jan 11, 2022 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Option exercise(M) | 964 | $2.15 | $2K |
| Jan 11, 2022 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Option exercise(M) | 964 | — | $0 |
| Jan 10, 2022 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Option exercise(M) | 36 | $2.15 | $77 |
| Jan 10, 2022 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Sell(S) | 36 | $12.00 | $432 |
| Jan 10, 2022 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Option exercise(M) | 36 | — | $0 |
| Dec 21, 2021 | Bonita David P | Director | Grant(A) | 13K | — | $0 |
| Dec 21, 2021 | Renaud Ronald C JR | Director | Grant(A) | 13K | — | $0 |
| Dec 21, 2021 | Dukes Iain D. | Director | Grant(A) | 23K | — | $0 |
| Dec 21, 2021 | Formela Jean Francois | Director | Grant(A) | 13K | — | $0 |
| Dec 21, 2021 | Stampacchia Otello | Director | Grant(A) | 13K | — | $0 |
| Dec 21, 2021 | Koehler Maria | Director | Grant(A) | 13K | — | $0 |
| Dec 14, 2021 | Atlas Venture Associates Opportunity I, LLC | 10% Owner | Sell(S) | 6K | $14.00 | $83K |
| Dec 14, 2021 | Formela Jean Francois | Director | Sell(S) | 6K | $14.00 | $83K |
| Dec 13, 2021 | Atlas Venture Associates Opportunity I, LLC | 10% Owner | Sell(S) | 8K | $14.64 | $122K |
| Dec 13, 2021 | Formela Jean Francois | Director | Sell(S) | 8K | $14.64 | $122K |
| Dec 10, 2021 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Sell(S) | 1K | $14.76 | $15K |
| Dec 10, 2021 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Option exercise(M) | 1K | $2.15 | $2K |
| Dec 10, 2021 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Option exercise(M) | 1K | — | $0 |
| Dec 10, 2021 | Atlas Venture Associates Opportunity I, LLC | 10% Owner | Sell(S) | 12K | $15.03 | $180K |
| Dec 10, 2021 | Formela Jean Francois | Director | Sell(S) | 12K | $15.03 | $180K |
| Nov 22, 2021 | Zhang Xiaoyan Michelle | Chief Scientific Officer | Grant(A) | 177K | — | $0 |
| Apr 15, 2021 | Koehler Maria | Director | Grant(A) | 27K | — | $0 |
| Mar 30, 2021 | Atlas Venture Associates Opportunity I, LLC | 10% Owner | Buy(P) | 125K | $16.00 | $2.0M |
| Mar 30, 2021 | Formela Jean Francois | Director | Buy(P) | 125K | $16.00 | $2.0M |
| Mar 30, 2021 | Atlas Venture Associates XI, LLC | 10% Owner | Conversion(C) | 1.1M | — | — |
| Mar 30, 2021 | Atlas Venture Associates XI, LLC | 10% Owner | Conversion(C) | 750K | — | — |
| Mar 30, 2021 | Atlas Venture Associates XI, LLC | 10% Owner | Conversion(C) | 2.9M | — | — |
| Mar 30, 2021 | Atlas Venture Associates XI, LLC | 10% Owner | Conversion(C) | 7.9M | — | — |
| Mar 30, 2021 | Atlas Venture Associates XI, LLC | 10% Owner | Conversion(C) | 11.3M | — | — |
| Mar 30, 2021 | Atlas Venture Associates XI, LLC | 10% Owner | Conversion(C) | 9.5M | — | — |
| Mar 30, 2021 | Atlas Venture Associates XI, LLC | 10% Owner | Conversion(C) | 5.4M | — | — |
| Mar 30, 2021 | Stampacchia Otello | Director | Conversion(C) | 1.8M | — | — |
| Mar 30, 2021 | Stampacchia Otello | Director | Grant(A) | 450K | $16.00 | $7.2M |
| Mar 30, 2021 | Stampacchia Otello | Director | Conversion(C) | 12.9M | — | — |
| Mar 30, 2021 | Formela Jean Francois | Director | Conversion(C) | 750K | — | — |
| Mar 30, 2021 | Formela Jean Francois | Director | Conversion(C) | 2.9M | — | — |
| Mar 30, 2021 | Formela Jean Francois | Director | Conversion(C) | 1.1M | — | — |
| Mar 30, 2021 | Formela Jean Francois | Director | Conversion(C) | 5.4M | — | — |
| Mar 30, 2021 | Formela Jean Francois | Director | Conversion(C) | 7.9M | — | — |
| Mar 30, 2021 | Formela Jean Francois | Director | Conversion(C) | 11.3M | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).